Type 2 Diabetes: Treatment Priorities in Primary Care

Curious about how primary care practitioners are managing the complexities of type 2 diabetes (T2D) in their practice?

Join our host Dr. Alice Cheng as she delves into this topic with Dr. James Kim, Clinical Assistant Professor in the Department of Family Medicine at the University of Calgary, lead editor for the Primary Care section of the Canadian Journal of Diabetes, and a key contributor within Diabetes Canada.

Our experts examine the critical role that primary care plays in the early diagnosis of T2D, personalizing and implementing treatment plans, and facilitating regular screening for potential complications. They stress the importance of managing both the physical and mental health of people living with diabetes, and provide practical strategies for organizing care and for maximizing the use of community resources.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Alice Cheng:

• Direct financial relationships, including receipt of honoraria: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MDBriefCase, LMC Physician Inc., Medscape, Humber River Health, Timed Right, The ACADEMY, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, American Diabetes Association. Membership on advisory boards or speakers’ bureaus: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi.

Dr. James Kim:

• Direct financial relationships, including receipt of honoraria: Abbott, AbbVie, AstraZeneca, Boehringer Ingelheim, Eisai, embecta, Eli Lilly, GSK, Janssen, Novo Nordisk, Pfizer, Sanofi, Takeda, Searchlight, Otsuka, Teva. Membership of advisory board or speakers’ bureaus: Abbott, AbbVie, ALK, AstraZeneca, Bayer, Boehringer Ingelheim, Eisai, embecta, Eli Lilly, GSK, Novo Nordisk, Sanofi, Teva, Takeda, Searchlight, Valeo. Funded grants, research, or clinical trials: Novo Nordisk. All other investments or relationships: MDBriefCase, CPD Network, Academy for Continued Advancement in Healthcare Education, EOCI, Family Physician Airway Group of Canada, Liv Agency, PPME, CCRN.

MAT-CA-2401556